JPET xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on January 28, 2005; DOI: 10.1124/jpet.104.081281


0022-3565/05/3133-1046-1057$20.00
JPET 313:1046-1057, 2005
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.104.081281v1
313/3/1046    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shmist, Y. A.
Right arrow Articles by Shainberg, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shmist, Y. A.
Right arrow Articles by Shainberg, A.

CARDIOVASCULAR

N,N,N',N'-Tetrakis(2-pyridylmethyl)-ethylenediamine Improves Myocardial Protection against Ischemia by Modulation of Intracellular Ca2+ Homeostasis

Yelena A. Shmist, Roman Kamburg, Gal Ophir, Alex Kozak, Vladimir Shneyvays, Yori J. Appelbaum, and Asher Shainberg

Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, Israel (Y.A.S., V.S., A.S.); and D-Pharm Ltd., Rehovot, Israel (R.K., G.O., A.K., Y.J.A.)

N,N,N',N'-Tetrakis(2-pyridylmethyl)-ethylenediamine (TPEN), a transition-metal chelator, was recently found to protect against myocardial ischemia-reperfusion injury. The goals of this study were to investigate the in vivo antiarrhythmic and antifibrillatory potential of TPEN in rats and guinea pigs and to study the in vitro effects of TPEN on calcium homeostasis in cultured newborn rat cardiac cells in normoxia and hypoxia. We demonstrated on an in vivo rat model of ischemia-reperfusion that TPEN abolishes ventricular fibrillation incidence and mortality and decreases the incidence and duration of ventricular tachycardia. To elucidate the mechanism of cardioprotection by TPEN, contraction, synchronization, and intracellular calcium level were examined in vitro. We have shown for the first time that TPEN prevented the increase in intracellular Ca2+ levels ([Ca2+]i) caused by hypoxia and abolished [Ca2+]i elevation caused by high extracellular Ca2+ levels ([Ca2+]o) or by caffeine. Addition of TPEN returned synchronized beating of cardiomyocytes desynchronized by [Ca2+]o elevation. To discover the mechanism by which TPEN reduces [Ca2+]i in cardiomyocytes, the cells were treated with thapsigargin, which inhibits Ca2+ uptake into the sarcoplasmic reticulum (SR). TPEN successfully reduced [Ca2+]i elevated by thapsigargin, indicating that TPEN did not sequester Ca2+ in the SR. However, TPEN did not reduce [Ca2+]i in the Na+-free medium in which the Na+/Ca2+ exchanger was inhibited. Taken together, the results show that activation of sarcolemmal Na+/Ca2+ exchanger by TPEN increases Ca2+ extrusion from the cytoplasm of cardiomyocytes, preventing cytosolic Ca2+ overload, which explains the beneficial effects of TPEN on postischemic cardiac status.


Received November 24, 2004; accepted January 20, 2005.

Address correspondence to: Prof. Asher Shainberg, Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan 52900, Israel. E-mail: shaina{at}mail.biu.ac.il







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics.